학술논문
Adjuvant durvalumab after concurrent chemoradiotherapy for patients with unresectable stage III NSCLC harbouring uncommon genomic alterations
Document Type
Article
Author
Source
In European Journal of Cancer May 2023 184:172-178
Subject
Language
ISSN
0959-8049